机译:术前伊立替康联合顺铂联合适形放疗,然后进行手术治疗食管癌的2期试验† sup>
Department of Medical Oncology, Princess Margaret and Toronto General Hospitals of the University Health Network, Toronto, Ontario, Canada;
Department of Radiation Oncology, Princess Margaret and Toronto General Hospitals of the University Health Network, Toronto, Ontario, Canada;
Department of Pathology, Princess Margaret and Toronto General Hospitals of the University Health Network, Toronto, Ontario, Canada;
Division of Thoracic Surgery, Department of Surgical Oncology, Princess Margaret and Toronto General Hospitals of the University Health Network, Toronto, Ontario, Canada;
Department of Biostatistics, Princess Margaret and Toronto General Hospitals of the University Health Network, Toronto, Ontario, Canada;
Department of Radiology, Princess Margaret and Toronto General Hospitals of the University Health Network, Toronto, Ontario, Canada;
esophageal cancer; trimodality therapy; irinotecan; cisplatin; radiation; surgery;
机译:术前伊立替康联合顺铂和适形放疗,然后进行食管癌手术的2期试验。
机译:食管癌中顺铂|伊立替康的诱导,同时顺铂|伊立替康的联合放疗和未经手术的放射治疗:多中心II期FFCD试验
机译:术前伊立替康-顺铂继之并用伊立替康-顺铂和放疗用于可切除的局部晚期胃和食管胃交界处腺癌的II期试验。
机译:在明确的化学疗法后食管癌持续术前术前CT检查,内窥镜检查和病理诊断的诊断
机译:东方合作肿瘤小组(E1201)食管腺癌新辅助术前紫杉醇/顺铂/放射治疗(RT)或伊立替康/顺铂/ RT的II期随机临床试验:长期结果及其对试验设计的影响
机译:食管癌中顺铂-伊立替康的诱导,顺铂-伊立替康的同步治疗以及未经手术的放射治疗:多中心II期FFCD试验